Lack of detection of circulating skin-specific IgE autoantibodies in dogs with moderate or severe atopic dermatitis

Human patients with atopic dermatitis (AD) commonly exhibit IgE reactivity to cutaneous self-antigens. The presence of serum IgE autoantibodies appears to correlate with disease severity, and it is suspected to reflect or contribute to tissue damage. The objective of this study was to determine whether IgE autoantibodies specific for cutaneous antigens could be detected in the serum of dogs with AD. Serum was collected from 19 dogs with untreated moderate to severe AD and four specific-pathogen free (SPF) dogs. Indirect immunofluorescence was performed using normal canine skin collected at four different locations (concave ear, nose, medial thigh and lateral thorax), while Western immunoblotting was done using normal canine ear pinna epidermal and dermal extracts and reducing conditions. In both methods, IgE was detected using a monoclonal antibody specific for heat stable epitopes of canine IgE. At 1:10 dilution, specific IgE autoantibodies against cutaneous autoantigens were not detected, with either method, in AD and SPF canine sera. Either IgE autoreactivity is not associated with moderate to severe AD in dogs, or the methods employed herein were not sensitive enough to permit IgE autoantibody detection.     

Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis

To evaluate the extent and severity of skin lesions in clinical trials enrolling dogs with atopic dermatitis (AD), the International Task Force on Canine Atopic Dermatitis recently recommended the use of the third version of the CADESI. This version of the CADESI was found to exhibit acceptable content, construct, criterion, inter- and intraobserver reliability and sensitivity to change. The current study was aimed at determining optimal CADESI-03 cut-off points to separate AD severity categories for future clinical trials. One hundred and eight dogs with AD were selected based on current diagnosis standards. At one or more visits, clinicians subjectively rated the severity of AD as 'in remission', 'mild', 'moderate' or 'severe', and a CADESI-03 score was then determined. In all, 158 CADESI-03 values were recorded and divided among the four disease severity categories. Receiver-operating characteristics (ROC) curves were generated at increasing cut-off values to determine the benchmark that would offer optimal sensitivity and specificity between adjacent categories. Cut-offs of 16, 60 and 120 are proposed at the interface of remission, mild, moderate and severe categories, respectively. Proposed intervals therefore are: remission: 0-15; mild AD: 16-59; moderate AD: 60-119; and severe AD: >/= 120. This Task Force recommends that, whenever applicable and relevant, subgroup analyses of outcome measures, based on disease severity as determined with these cut-off CADESI-03 values, be preplanned for clinical trials enrolling dogs with AD. Such subgroup analyses could help determine whether specific interventions might be more effective in a particular subset of atopic dogs.     

Comparison of the lesions of Aleutian disease in mink and hypergammaglobulinemia in ferrets.

Gross and microscopic lesions of Aleutian disease (AD) in mink and hypergammaglobulinemia in ferrets were compared. Both conditions were characterized by widespread proliferation of plasma cells, but proliferation was more prominent in mink infected with AD. Arteritis did not occur in hypergammaglobulinemic ferrets. Minimal or no glomerular alterations occurred in infected ferrets, but were severe in mink infected with AD. Bile duct proliferation was more prominent in diseased mink. Tissue alterations suggested that AD in Aleutian genotype mink is more rapidly progressive than is AD in ferrets, causing overt clinical disease and death. In contrast, hypergammaglobulinemia in ferrets appeared to progress more slowly, with little clinical evidence of disease. This is probably the result of a paucity of glomerular lesions in ferrets. Possible mechanisms to explain the differences in the development of lesions are discussed.     

水貂阿留申病的防制

简述了阿留申病对养貂业的严重危害及其症状和病原性。概述了当前此病的 3种防制措施 :应用对流免疫电泳 (CIEP)特异诊断阿留申病 (AD) ,淘汰阳性貂 ,净化种群 ;筛选抗阿留申病个体 ,进行抗病育种 ;研制疫苗 ,开展免疫预防综合性防制。     

Transmission electron microscopy studies in an experimental model of canine atopic dermatitis

Impairment of skin barrier function has been hypothesized in canine atopic dermatitis (AD). In this prospective, controlled study, the ultrastructure of the upper epidermal layers was investigated using an experimental model of canine AD. Seven atopic Beagles sensitized to Dermatophagoides farinae and four healthy Beagles were used as controls. Both normal and atopic dogs were challenged with D. farinae for 3 days. Clinical signs were scored and skin biopsies were taken from the inguinal area before and 3 days after allergen exposure. Samples were processed to enhance lipid visibility and evaluated by Transmission Electron Microscopy. Emphasis was placed on evaluation of the lipid lamellae (LL), and lamellar bodies (LB) of the stratum corneum.
After allergen challenge, atopic Beagles developed severe pruritic dermatitis while no skin lesions were noted in the controls. Ultrastructurally, before allergen challenge, atopic Beagles displayed focally severe abnormalities in LL organization and wider intercellular spaces containing abnormal lipid material. In atopic Beagles, LBs were frequently found inside corneocytes while this finding was not observed in the controls. After allergen challenge, further increase of intercellular spaces was observed in the stratum corneum of atopic Beagles while no appreciable changes were observed in the normal dogs. Intercellular spaces in atopic Beagles were filled with abundant amounts of abnormal lipid material and highly disorganized LL. It is concluded that baseline differences in the ultrastructure of the skin exist between normal and experimentally sensitized atopic Beagles and that these changes are aggravated by allergen challenge and the resulting flare-up of dermatitis.     

Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis

Background – Interleukin‐31 (IL‐31) is a member of the gp130/interleukin‐6 cytokine family that is produced by cell types such as T helper 2 lymphocytes and cutaneous lymphocyte antigen positive skin homing T cells. When overexpressed in transgenic mice, IL‐31 induces severe pruritus, alopecia and skin lesions. In humans, IL‐31 serum levels correlate with the severity of atopic dermatitis in adults and children. Hypothesis/Objective – To determine the role of IL‐31 in canine pruritus and naturally occurring canine atopic dermatitis (AD). Animals – Purpose‐bred beagle dogs were used for laboratory studies. Serum samples were obtained from laboratory animals, nondiseased client‐owned dogs and client‐owned dogs diagnosed with naturally occurring AD. Methods – Purpose‐bred beagle dogs were administered canine interleukin‐31 (cIL‐31) via several routes (intravenous, subcutaneous or intradermal), and pruritic behaviour was observed/quantified via video monitoring. Quantitative immunoassay techniques were employed to measure serum levels of cIL‐31 in dogs. Results – Injection of cIL‐31 into laboratory beagle dogs caused transient episodes of pruritic behaviour regardless of the route of administration. When evaluated over a 2 h period, dogs receiving cIL‐31 exhibited a significant increase in pruritic behaviour compared with dogs that received placebo. In addition, cIL‐31 levels were detectable in 57% of dogs with naturally occurring AD (≥13 pg/mL) but were below limits of quantification (<13 pg/mL) in normal, nondiseased laboratory or client‐owned animals. Conclusions – Canine IL‐31 induced pruritic behaviours in dogs. Canine IL‐31 was detected in the majority of dogs with naturally occurring AD, suggesting that this cytokine may play an important role in pruritic allergic skin conditions, such as atopic dermatitis, in this species.     

Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: a retrospective case-control study

In human medicine, the relationship between the immunodysregulation observed in atopic dermatitis (AD) and the development of mycosis fungoides (MF) has triggered considerable interest due to the increasing number of patients with MF who have a previous history of AD. The purpose of this retrospective case-control study was to investigate whether dogs diagnosed with MF were more likely to have AD. The records of 96 000 canine patients at the University of Florida were searched. Inclusion criteria were a clinical and histological diagnosis of MF. Dogs admitted to the University of Florida, Veterinary Medical Center during the same time period (1991-2004) without a diagnosis of MF were included as controls. Four controls for each study dog were randomly selected (matched by year of admission). Frequency of AD and other exposure variables were compared among case and control dogs by using conditional logistic regression. Records of 19 dogs with a diagnosis of MF were identified. Five of them (5/19, 26.3%) had previous diagnosis of AD. The odds of having MF was 12 times (OR = 12.54; 95% CI = 1.95-80.39; P < 0.01) higher in dogs with AD than in dogs without AD. In conclusion, this study suggests an association between AD and MF in dogs. Future studies are necessary to confirm this finding and to investigate the pathogenic mechanisms involved in this association.     

Decreasing half-life of dieldrin in egg yolk following a single oral administration of aldrin to laying hens

Laying hens were treated orally with a single dose of aldrin (AD) 1 mg/kg body weight. Concentrations (microgram/g) of AD or its epoxide (= dieldrin, DD) in the yolk of eggs laid for 21 days after AD treatment were determined by normal-phase high-performance liquid chromatography. The limits of determination were 0.02 microgram/g for AD and 0.03 microgram/g for DD, respectively. After AD treatment, although the low levels of AD (mean 0.02-0.03 microgram/g) were observed only during a three-day period (from 4th to 6th days), DD (mean 0.15 microgram/g) was found already on the 2nd day, indicating that the epoxidation of AD to DD in the hen's body is rapid. The highest level of DD (mean 0.40 microgram/g) was detected on the 6th day, and then DD levels decreased slowly and were detected up to the 21st day. In this decreasing phase, the half-life of DD in the yolk was estimated to be 25.6 days with a 95% confidence interval from 22.7 to 29.4 days.     

Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls

As in humans, there is mounting evidence in support of an abnormal skin barrier contributing to the pathogenesis of canine atopic dermatitis (AD). Studies in people with AD have associated an abnormal skin barrier with deficiencies in ceramides, which represent important components of the stratum corneum (SC) intercellular lipid lamellae. Therefore, the goal of this study was to determine if the SC of dogs with AD is deficient in ceramides compared to normal dogs. Samples of SC were obtained from nonlesional skin of the caudal abdomen of 14 patients with AD and 14 age-, breed- and sex-matched healthy controls using a cyanoacrylate stripping procedure, and the subclass and relative amount of ceramides were assessed blindly by thin layer chromatography. Paired t -tests using R statistical computer software revealed the percentage amounts of ceramides 1 and 9 were significantly lower in nonlesional skin of AD dogs compared to controls ( P = 0.034 and P = 0.047, respectively), and the cholesterol percentage amount was significantly higher in AD dogs than in controls ( P = 0.016). Furthermore, the cholesterol/ceramide ratio was significantly higher in the AD group with respect to controls ( P = 0.014). These findings suggest that decreased amounts of ceramides in the skin of dogs with AD may be involved in the impaired barrier function of their skin.     

Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation

REASON FOR PERFORMING STUDY: Good results have been obtained with a human amiodarone (AD) i.v. protocol in horses with chronic atrial fibrillation (AF) and a pharmacokinetic study is required for a specific i.v. amiodarone treatment protocol for horses. OBJECTIVES: To study the efficacy of this pharmacokinetic based i.v. AD protocol in horses with chronic AF. METHODS: Six horses with chronic AF were treated with an adapted AD infusion protocol. The protocol consisted of 2 phases with a loading dose followed by a maintenance infusion. In the first phase, horses received an infusion of 6.52 mg AD/kg bwt/h for 1 h followed by 1.1 mg/kg bwt/h for 47 h. In the second phase, horses received a second loading dose of 3.74 mg AD/kg bwt/h for 1 h followed by 1.31 mg/kg bwt/h for 47 h. Clinical signs were monitored, a surface ECG and an intra-atrial electrogram were recorded. AD treatment was discontinued when conversion or any side effects were observed. RESULTS: Three of the 6 horses cardioverted successfully without side effects. The other 3 horses did not convert and showed adverse effects, including diarrhoea. In the latter, there were no important circulatory problems, but the diarrhoea continued for 10-14 days. The third horse had to be subjected to euthanasia because a concomitant Salmonella infection worsened the clinical signs. CONCLUSION: The applied treatment protocol based upon pharmacokinetic data achieved clinically relevant concentrations of AD and desethylamiodarone. POTENTIAL RELEVANCE: Intravenous AD has the potential to be an alternative pharmacological treatment for AF in horses, although AD may lead to adverse drug effects, particularly with cumulative dosing.     

Protein and amino acid metabolism in the intestinal tract of growing young bulls. 7. Protein estimation and evaluation of protein supply in growing ruminants by the apparently digestible total protein in the duodenum based on rations

The following values were derived from experimental studies of the crude protein (CP) and amino acid (AA) metabolism of growing fattening bulls, the detailed results of which were described in installments 1-6, for the ascertainment of the content of apparently digestible total protein at the duodenum (ADTPD): a) partial method: Degradation quotaCP = NPN + 0.69 X g pure protein/CP; g AD feed PD = g CP (1 -decomposition quotaCP) X 0.72 or g AD feed PD = 0.31 X g pure protein X 0.72; g ADBPDE = 0.149 X g AD org. matter X 0.80 X 0.72 (ADBPDE = apparently digestible pure bacteria protein at the duodenum, dependent on energy release in the reticulo-rumen; g ADBPDN = g CP X (degradation quotaCP) X 0.80 X 0.72 (ADBPDN = apparently digestible pure bacteria protein at the duodenum, dependent on CP supply of rumen microbes); g AD total PD = g AD feed PD + ADBPDE g AD total PD = g AD feed PD + ADBPDN; b) summarizing method: AD total PD = 0.429 + 10.9 X 0.80/CP in % AD org. matter X (CP intake) X 0.72; AD total PD = 0.196 + 16.6 X 0.80/pure protein % AD org. m. X pure pr. intake X 0.72. The requirement of AD total PD was calculated under consideration of the endogenous urine N, skin N and hair N losses as well as protein retention per kg live weight assuming a utilization of 0.70 for this partial performance. The practical application of this balance method is demonstrated in comparison to the digestible CP-system.     

基于形态性状及Adh1基因序列的芒与五节芒自然杂交现象研究

本研究通过对13份芒与五节芒17个形态性状及Adh1基因序列的分析,探讨了芒与五节芒的自然杂交现象。形态性状聚类分析结果表明,疑似杂交种AD431与五节芒类群(AA335和AD625)聚为一类,疑似杂交种AA343、AD431、AD628、AD607、AD633和AD606与芒类群(AD623、AD512、AD620、AD619和AD627)聚为一类。Adh1基因序列聚类分析结果表明,五节芒和芒的材料分别聚成2个明显分开的分支,所有的疑似杂交种中均检测到2种Adh1基因单倍型的存在,其中1个单倍型在系统树中与芒聚为一类,另1个单倍型与五节芒聚为一类。本研究的结果确证了AD431、AD431、AD628、AD607、AD633和AD606这6个疑似杂交种的真实性,证实了芒与五节芒种间确实存在自然杂交现象,为进一步阐明芒和五节芒的系统进化与亲缘关系提供了重要的理论依据。     

First case report of ultrastructural cutaneous abnormalities in equine atopic dermatitis

Atopic dermatitis (AD) is a common skin disease that affects humans and animals. Skin impairment has been described in human and canine AD. Equine AD is recognized in practice but little is known about its pathogenesis. As remarkable similarities exist across species in terms of cutaneous manifestations of AD, it was speculated that skin abnormalities may also exist in atopic horses. This case report describes the ultrastructure of the stratum corneum of two normal and two atopic horses. Biopsies were taken from sites predisposed to AD and examined using electron microscopy. Stratum corneum in normal samples was compacted with organized lipid lamellae while in atopic samples disorganized lipid lamellae, retained lamellar bodies and amorphous lipids were found. These changes are very similar to what reported in AD in other species. It is currently unknown whether these abnormalities in atopic horses are primary or secondary and their importance in allergen penetration.     

Intradermal skin test reactivity to histamine and substance P is blunted in dogs with atopic dermatitis

Skin reactivity to intradermal injections (0.1, 0.5 and 1 nm ) of substance P (SP) was evaluated in 20 clinically normal dogs and 20 dogs with atopic dermatitis (AD). Saline and histamine were used as negative and positive controls, respectively. Wheal diameters were measured. Reactions were evaluated for erythema and induration and a subjective score, on a scale from 0 to 4+, was given. Evaluations were performed at 3, 5, 10, 15 and 30 min after the injections. Wheal diameters for histamine and SP injections were significantly smaller in dogs with AD compared with clinically normal dogs. In both groups, reactions to the various concentrations of SP were not significantly different from each other and were always smaller than histamine reactions. Erythema was not seen with SP injections. In addition, subjective scores for SP injections were significantly lower in dogs with AD compared with controls. The results of this study are similar to those reported in human medicine, where a role for SP in AD is proposed and desensitization of receptors to both SP and histamine is hypothesized. Further studies are needed to investigate the role of SP in the pathogenesis of canine AD.     

猪瘟活疫苗佐剂稀释剂的制备及免疫效果评价

本试验旨在针对性的研发一种安全性好、能有效增强免疫效果、使用方便的猪瘟活疫苗新型佐剂稀释剂(AD),并对AD的免疫增强效果进行评价。采用高压均质技术制备了AD,采用响应面试验设计优化了AD的处方和制备工艺,并对其稳定性、粒径、多分散指数(PDI)及Zeta电位进行表征。将AD与猪瘟活疫苗混合后,肌肉注射免疫BALB/c小鼠,进行佐剂增强免疫效果评价。优化处方和工艺制备的AD平均粒径为100.4 nm,PDI为0.147,Zeta电位为-28.7 mV,试验结果表明其稳定性良好。免疫效果评价试验结果显示,佐剂组小鼠血清中抗猪瘟病毒(CSFV)抗体水平与对照组相比有显著差异(P<0.05),抗体水平能持续较长时间,表明AD能有效诱导机体产生体液免疫应答;佐剂组小鼠血清中IL-4、IL-6和IFN-γ的水平均有明显提高,表明该疫苗佐剂能诱导机体产生细胞免疫应答。本试验制备的佐剂稀释剂与疫苗混合使用,能显著提高体液免疫和细胞免疫水平,从而增强疫苗的免疫刺激能力。     

Preparation of Adjuvant Diluent for Live Vaccine against Classical Swine Fever and Evaluation of its Immune Effects

The aim of this study was to develop a novel oil-in-water (O/W) emulsion as adjuvant diluents (AD) for live vaccine against classical swine fever (CSF) that could effectively enhance the immune effect of vaccine.The AD was prepared by high-pressure homogenization technique.Formulations and preparation parameters were optimized with response surface design.Its stability, particle size, polydispersity (PDI) and Zeta potential were characterized.The humoral immune response and cellular immune response of the AD were evaluated with BALB/c mice by intramuscular injection.The particle size of the AD prepared by optimized formulation and parameters was 100.4 nm, PDI was 0.147, and Zeta potential was —28.7 mV.The experiment results showed that the AD had good stability.The AD was inoculated combined with live vaccine against CSF into BALB/c mice by intramuscular injection.The results showed that the live vaccine against CSF specific immune responses could be evoked in mice by co-inoculation with AD and vaccine.The cellular immune response levels in co-inoculated groups were significantly higher than control group (P<0.05), with obvious phenomena of higher levels of IFN-γ, IL-6 and IL-4 in serum.The result revealed that cellular immune capability significantly improved with the AD.The results strongly revealed that cellular immune capability significantly improved by introducing AD for effective immune-adjuvant for live vaccine against CSF.     

FC-35 Real-time evaluation of cytokine and protease expression in flea-allergic and nonallergic dogs

Atopic dermatitis (AD) is very common in dogs, but its pathogenesis is not yet fully understood. It has been suggested that a Th2-dominant status may be associated with the occurrence of canine AD. IL-12 is thought to be important for the differentiation of Th1 cells. The IL-12 receptor β2 (IL-12Rβ2) gene is considered to play a critical role in signal transduction and is attracting attention as one of the causative genes of AD in humans. The purpose of this study was to investigate the relationship between IL-12Rβ2 gene expression and canine AD. The canine IL-12Rβ2 gene was cloned by RT-PCR and its nucleotide sequences were determined. Canine IL-12Rβ2 showed 76.8% homology at the amino acid level with human IL-12Rβ2, and its structural motifs were well conserved. cDNA with a 91 bp deletion including the transmembrane region was also cloned, which consequently produced a frame shift and an early stop codon. The deletion region corresponded to exon 14 of the human IL-12Rβ2 gene on chromosome 1. The expression of deleted canine IL-12Rβ2 mRNA in phytohemagglutinin-stimulated peripheral blood mononuclear cells was examined in seven healthy dogs and 11 AD dogs. Both deleted and intact mRNAs were expressed at constant ratios in healthy and AD dogs. The results indicate that the deletion of the transmembrane region is not associated with the occurrence of AD, and that the expression of the deleted mRNA may be constitutive and produced by alternative splicing.
Funding: Self-funded.